Specific human leukocyte antigen (HLA) alleles are associated with the formation of anti-drug antibodies to adalimumab in patients with rheumatoid arthritis and hidradenitis suppurativa, potentially causing reduced therapeutic response.
Specific human leukocyte antigen (HLA) alleles are associated with the formation of anti-drug antibodies to adalimumab in patients with rheumatoid arthritis (RA) and hidradenitis suppurativa (HS), potentially causing reduced therapeutic response, according to recent research by Mohan Liu, PhD, and colleagues published online in PLoS One.
Although certain HLA alleles are known to be associated with antibody formation against infliximab, the role of patient-related factors in determining anti-adalimumab antibody formation had not previously been shown. The results suggest that specific HLA alleles may play a key role in developing these antibodies in patients with RA and HS treated with adalimumab, the authors conclude.
The study received funding from AbbVie, maker of reference adalimumab (Humira). Two biosimilar adalimumab products have been approved by the FDA.
The researchers drew their study subjects from participants in 4 different phase 3 clinical trials that enrolled patients with RA or HS at sites predominantly in the United States and Europe. Patients with RA received subcutaneous injections of 40 mg of adalimumab every other week for up to 24 weeks, as well as weekly oral doses of methotrexate; patients with HS received 40 mg subcutaneous adalimumab injections every week or every other week for up to 36 weeks.
Samples from 634 subjects with either RA or HS were analyzed. Of this group, 37 subjects (17 with RA, 20 with HS) developed antibodies to adalimumab during treatment, and 597 subjects (348 with RA, 249 with HS) did not develop these antibodies during the clinical trials.
Using next-generation sequencing-based HLA typing, the researchers identified 3 specific protective HLA alleles that were less prevalent in antibody-positive subjects than in antibody-negative subjects (odds ratios [OR]: 0.4, 0.25, and 0.28, respectively) and 2 risk HLA alleles that were more abundant in antibody-positive than in antibody-negative subjects (OR: 2.52 and 2.64, respectively).
The 3 protective alleles were:
The 2 risk alleles were:
The researchers report that HLA-DRB1*03 is independently predictive of antibody formation in patients with RA and HS with adalimumab treatment and in patients with inflammatory bowel disease receiving infliximab treatment. “These results provide additional insight into underlying reasons for variable immunogenicity response across different patients treated with [anti—tumor necrosis factor] therapy,” they conclude.
Reference
Liu M, Degner J, Davis JW, Idler KB, Mostafa N, Waring JF. Identification of HLA-CRB1 association to adalimumab immunogenicity. PLoS One. 2018;13(4):e0195325. doi: 10.1371/journal.pone.0195325.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.